Gilead seeks share number doubling to support M&A, defense
This article was originally published in Scrip
Executive Summary
Gilead Sciences, which made a whopper acquisition last year to build its hepatitis C research program, is asking its shareholders for flexibility to act quickly on other potential takeovers.